Research context
A prescription GLP-1 receptor agonist. Use only under qualified medical supervision.
Regulatory note: Verify local laws, product approval and professional guidance before any human use. This profile is not a recommendation for use.
GLP-1 medicine
Semaglutide
A prescription GLP-1 receptor agonist. Use only under qualified medical supervision.
101 connected records58 graded citations0 external identifiers
Evidence map
Claims linked to original records.
Evidence levels describe study design. They do not by themselves establish safety or effectiveness.
Gorgul YA, Zaitsev AV · International Journal of Molecular Sciences
GLP-1 Receptor Agonists in Epilepsy: Separating Evidence for Antiseizure Activity, Neuroprotection, and Disease Modification.
pmc 2026
Petersen J, Merrild C, Holm SK, Kurgan N, Hassan S, Mathiesen CV, Börchers S, Svendsen C, D'Anna S, Andersen NR, Klein AB, Fritzen AM, Deshmukh AS, Pers TH, Clemmensen C
Cagrilintide and retatrutide combination therapy enhances weight loss and metabolic outcomes in obese male rats.
pubmed
Bawadi H, Abuhijleh H, Nofal M, Zakaria ZZ, Al-Asmakh M
Impact of Semaglutide, Liraglutide and Tirzepatide on Cardiometabolic Outcomes: A Comparative Narrative Review.
pubmed 2026
Moubarak ES, Elgendy MS, Elkoumi O, Ibrahim AA, Manasrah A, Ahmad J, Hassan MA, Rageh OE, Mohamed AA, Elzahaby A, Abuelazm M
Adjunctive GLP-1 receptor agonists for cardiometabolic risk in antipsychotic-treated patients: A GRADE-assessed meta-analysis of randomized trials.
pubmed
Mathew A, Anwar H
Assessing the Growing Impact of Oral GLP-1 Agonists on National Obesity Policies of the United Kingdom.
pubmed 2026
Raj FP, Boo H, Kenney A, Espiridion E
Investigating the Association Between Semaglutide Use and Mood Disorders in Polyendocrine Metabolic Ovarian Syndrome: A Retrospective Cohort Study.
pubmed 2026
You Z, Yang L, Long Y, You D, Zhao Q
A new era in the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD): clinical breakthroughs and challenges.
pubmed 2026
Melnikov I, Borodko D, Alekseev V
Beyond Weight Loss: Thromboinflammation as a Candidate Mechanism for the Cardiovascular Benefit of GLP-1 Receptor Agonists.
pubmed
Thome AD, Wang J, Faridar A, Zhao W, Saetzler V, Beers DR, Appel SH
Combination GLP-1RA and Low-Dose IL-2 Modulates Peripheral Immune Activation and Attenuates CNS Inflammatory Transcript Signatures In Vivo.
pubmed
The investigators propose a proof of concept RCT (randomized clinical trial), testing the efficacy of intranasal insulin (INI) with semaglutide, a combination therapy with strong biological plausibility to benefit impaired cognition through vascular mechanisms, in older adults with MetS (metabolic syndrome) and MCI (Mild Cognitive...
COMMETS- Combination MCI Metabolic Syndrome
clinicaltrials 2022
Overweight/obese otherwise healthy volunteers will be recruited from the Old Order Amish population in Lancaster County, PA. Lancaster County, PA. Pharmacodynamic responses to GLP1R agonist will be assessed by conducting frequently sampled intravenous glucose tolerance tests (FSIGT) both before and after semaglutide for six weeks....
Pharmacogenetics of Response to GLP1R Agonists
clinicaltrials 2021
This trial is conducted globally. The aim of the trial is to investigate efficacy and long-term safety of oral semaglutide versus sitagliptin in subjects with type 2 diabetes.
Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes
clinicaltrials 2015
This randomized study evaluates the effect of subcutaneous semaglutide /in combination with lifestyle counseling in patients with type 2 diabetes mellitus (T2DM), overweight/obesity, and stage 4-5 chronic kidney disease (CKD) or dialysis-dependent end-stage kidney disease (ESKD) on patients' eligibility for kidney transplantation at the end...
Effect of Subcutaneous Semaglutide on Kidney Transplant Candidacy
clinicaltrials 2021
This study will compare the effect of semaglutide once weekly to insulin aspart 3 times daily as add on to metformin and insulin glargine in people with type 2 diabetes. Participants will either get insulin glargine and semaglutide or insulin glargine and insulin aspart -...
A Research Study to Compare Semaglutide to Insulin Aspart, When Taken Together With Metformin and Insulin Glargine, in People With Type 2 Diabetes
clinicaltrials 2018
Phase 2 Safety, Efficacy and, Tolerability of Fixed Dose Combination of Aroxybutynin/Atomoxetine (AD109) in Obstructive Sleep Apnea Patients Taking Tirzepatide, Semaglutide or Liraglutide
Study That Tests AD109 in Patients Taking GLP-1 Drugs
clinicaltrials 2024
This study will look at how much weight participants will lose from the start to the end of the study. The weight loss in participants taking the investigational high dose of semaglutide will be compared to the weight loss in people taking "dummy" medicine and...
A Research Study to See How Semaglutide Helps People With Excess Weight, Lose Weight (STEP UP)
clinicaltrials 2022
This study is designed to determine whether therapy with once-weekly sc semaglutide in combination with once-daily insulin degludec will be capable of maintaining (or improving) glycemic control, when substituted for multiple daily injections of insulin (MDI), in patients with T2D with adequate glycemic control (≤...
Transition From Basal/Bolus to Once-weekly Subcutaneous Semaglutide and Basal Insulin in Patients With T2D
clinicaltrials 2020
Roach KA, Khazaee M, Mohar I, Boon D, Cronin B, Gauthier AG
Suitability of the ICH S1B(R1) Weight-of-Evidence Framework to Evaluate Glucagon-Like Protein-1 Receptor Agonist (GLP-1RA) Carcinogenicity Risk.
pubmed
Ayyaz F, Khan H, Zia I
Oral semaglutide vs DPP-4 inhibitors in reducing risk of cognitive impairment in elderly patients with HFpEF and obesity.
pubmed
Bandaranaike R, Rutland T, Rutland B
Glucagon-like Peptide-1 Receptor Agonists and Upper Gastrointestinal Endoscopy: A Narrative Review of Residual Gastric Contents Aspiration Risk and Periprocedural Management.
pubmed
Dinkov B, Koleva N, Stavreva G
Salcaprozate Sodium as a Permeation Enhancer-Mechanism, Applications and Unresolved Questions.
pubmed
Ferician AC, Ghitea TC, Popoviciu MS
Clinical Profile of Documented Diabetic Peripheral Neuropathy by GLP-1-Based Medication Status: A Cross-Sectional Study.
pubmed
Enache V, Popescu DC, Marcu B, Diaconu M, Nechita AC
Cardiovascular-Kidney-Metabolic Syndrome and Its Hepatic Dimension: A Narrative Review.
pubmed
Kaltsas A, Gkioxaris V, Giannakas T, Zachariou A, Dimitriadis F, Sofikitis N, Chrisofos M
GLP-1 Receptor Agonists and Tirzepatide in Men Seeking Fertility: A Structured Narrative Review and Proposed Clinical Framework.
pubmed
Jiang W, Fukunaga K, Kobayashi T, Saheki T, Yoshimura T, Zhang H, Ly R, Imachi H, Murao K
GLP-1 Receptor Agonists as Molecular Relievers of Lipotoxic Stress: From Pancreatic Beta-Cell Cholesterol Efflux to Systemic and Tissue-Specific Metabolic Protection.
pubmed
There is increasing interest in using GLP-1 Receptor Agonist (GLP-1 RA) medications after pregnancy. This study is designed to determine if these medications affect breastmilk production or the nutritional makeup of breastmilk. The main questions the study will address are: * Does GLP-1 RA-induced weight...
Effects of GLP-1 RAs on Human Lactation Outcomes
clinicaltrials 2026
This study is done to find out whether the medicine, semaglutide, has a positive effect on early Alzheimer's disease. Participants will either get semaglutide or placebo (a "dummy" medicine which does not contain any study medicine) - which treatment participants get is decided by an...
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)
clinicaltrials 2021
The risk of type 2 diabetes appears to be higher in patients with chronic inflammatory diseases, including chronic inflammatory bowel disease (IBD). IBD is a group of inflammatory diseases that includes mainly Crohn's disease and ulcerative colitis. Although the majority of IBD patients are not...
Interest of GLP1 Analogues in Overweight Type 2 Diabetic Patients With Chronic Inflammatory Bowel Disease
clinicaltrials 2021
The goal of this clinical trial is to evaluate the efficacy and safety of Bofanglutide (GZR18) compared with Semaglutide in Latin American adults with type 2 diabetes mellitus who have inadequate glycemic control while receiving stable metformin monotherapy. The main questions it aims to answer...
BALANCE-DM2 Study of Bofanglutide in Adults With Type 2 Diabetes
clinicaltrials 2026
This trial is conducted in Europe. The aim of the trial is to investigate the effect of food on the pharmacokinetics (the exposure of the trial drug in the body) of oral semaglutide, in a SNAC (sodium N-\[8-(2-hydroxybenzoyl) amino\] caprylate) tablet formulation with three different...
Effect of Food on the Pharmacokinetics of Oral Semaglutide in Healthy Subjects
clinicaltrials 2014
Minorities have higher rates of diabetes, poorer glucose control, and higher complications and mortality rates than white people. Several recently approved diabetes medicines improve cardiovascular and renal outcomes through two different mechanisms. This study will explore key determinants of blood glucose levels namely beta cell...
Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists
clinicaltrials 2025
This study will compare the new medicine IcoSema, which is a combination of insulin icodec and semaglutide, taken once a week, to insulin icodec taken once a week in people with type 2 diabetes. The study will look at how well IcoSema controls blood sugar...
A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Insulin Icodec
clinicaltrials 2022
This study compares the effect and safety of 2 dose schedules for semaglutide (study medicine) in people with type 2 diabetes previously treated with a diabetes medicine similar to semaglutide. The study will also evaluate the use of a new pen-injector for semaglutide used to...
SUSTAIN SWITCH: A Research Study to Compare Two Dose Schedules of Semaglutide Taken Once Weekly in People With Type 2 Diabetes
clinicaltrials 2020
Fairy R, Ali L, Azam H, Khurram A, Shahzaib M, Tariq H, Rashmeen S, Hassan H · Research in heart yield and translational medicine
Efficacy of Semaglutide in Modulating Cardiac Remodeling in Mice: A Review of Mechanisms and Outcomes.
pmc 2026
Sotzen MR, Byun S, Ibadin NO, Knappenberger MA, Bento MT, Asker M, Koshkin S, Diaz FJ, Skibicka KP · Molecular metabolism
Beyond weight loss: Disentangling the direct effects of semaglutide vs equivalent calorie restriction on reproductive systems of male and female rats.
pmc
Atal S, Agrawal C, Gupta R, Sadasivam B · Indian journal of pharmacology
Pharmacological management of obesity: Current landscape and emerging therapies.
pmc
AlTaweel MO, Ahmed Jalbani A, Memon F, Aly Mahmoud A, Memon P, Elnasharty I, Elshehawey A, Al Qarni A · Journal of Personalized Medicine
Exploratory Biomarker-Defined Phenotypic Heterogeneity Beyond a Single Physiological Reserve Construct.
pmc 2026
Jiang W, Fukunaga K, Kobayashi T, Saheki T, Yoshimura T, Zhang H, Ly R, Imachi H, Murao K · International Journal of Molecular Sciences
GLP-1 Receptor Agonists as Molecular Relievers of Lipotoxic Stress: From Pancreatic Beta-Cell Cholesterol Efflux to Systemic and Tissue-Specific Metabolic Protection.
pmc 2026
Dinkov B, Koleva N, Stavreva G · Pharmaceutics
Salcaprozate Sodium as a Permeation Enhancer—Mechanism, Applications and Unresolved Questions.
pmc 2026
Pavshintsev VV, Erbaeva AZ, Vatlin AA, Mitkin NA · Biomedicines
Semaglutide Attenuates Inflammatory Macrophage Polarization and Promotes Changes Associated with Mitochondrial Biogenesis Through cAMP-Dependent Signaling.
pmc 2026
Zhao Z, Hu X · Biomedicines
Pathogenesis-Informed Phenotype-Guided Therapy for MASH: A Three-Axis Translational Framework Within the MASLD Spectrum.
pmc 2026
· Royal Pharmaceutical Society
semaglutide
crossref
· Royal Pharmaceutical Society
semaglutide
crossref
· Springer Science and Business Media LLC
Semaglutide
crossref 2024
· Springer Science and Business Media LLC
Semaglutide
crossref 2025
M van den Berg · Geneesmiddelenbulletin Foundation
Orale semaglutide versus subcutane semaglutide
crossref 2026
· Wiley
Review for "Semaglutide 25 mg Oral versus Semaglutide 2.4 mg Injectable: An Indirect Treatment Comparison of Weight Loss Outcomes"
crossref 2026
· Wiley
Review for "Semaglutide 25 mg Oral versus Semaglutide 2.4 mg Injectable: An Indirect Treatment Comparison of Weight Loss Outcomes"
crossref 2026
· Wiley
Review for "Semaglutide 25 mg Oral versus Semaglutide 2.4 mg Injectable: An Indirect Treatment Comparison of Weight Loss Outcomes"
crossref 2026
Steven P. Marso, Stephen Charles Bain, Agostino Consoli, Freddy Goldberg Eliaschewitz, Esteban Jódar, Lawrence A. Leiter et al. · New England Journal of Medicine · 6912 citations
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
openalex 2016
John P.H. Wilding, Rachel Louise Batterham, Salvatore Calanna, Melanie J. Davies, Luc F. Van Gaal, Ildiko Lingvay et al. · New England Journal of Medicine · 5058 citations
Once-Weekly Semaglutide in Adults with Overweight or Obesity
openalex 2021
Abraham Michael Lincoff, Kirstine Brown‐Frandsen, Helen Martina Colhoun, John Eric Deanfield, Scott S. Emerson, Sille Esbjerg et al. · New England Journal of Medicine · 3061 citations
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
openalex 2023
Mansoor Husain, Andreas L. Birkenfeld, Morten Donsmark, Kathleen Marie Dungan, Freddy Goldberg Eliaschewitz, Denise Reis Franco et al. · New England Journal of Medicine · 2009 citations
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
openalex 2019
Philip Noel Newsome, Kristine Buchholtz, Kenneth J. Cusi, Martin Linder, Takeshi Okanoue, Vlad Ratziu et al. · New England Journal of Medicine · 2009 citations
A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis
openalex 2020
Juan P. Frías, Melanie J. Davies, Julio Rosenstock, Federico C. Pérez Manghi, Laura Fernández Landó, Brandon K. Bergman et al. · New England Journal of Medicine · 2036 citations
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
openalex 2021
Vlado Perkovic, Katherine R. Tuttle, Peter R Rossing, Kenneth W. Mahaffey, Johannes F.E. Mann, George L. Bakris et al. · New England Journal of Medicine · 1828 citations
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes
openalex 2024
Mikhail Kosiborod, Steen Zabell Abildstrom, Barry A. Borlaug, Javed Butler, Søren Rasmussen, Melanie J. Davies et al. · New England Journal of Medicine · 1621 citations
Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity
openalex 2023
Myśliwczyk D, Myśliwiec M, Minarowska A, Wasilewska E · International Journal of Molecular Sciences
GLP-1 and Dual GIP/GLP-1 Receptor Agonists in Pediatric Obesity: From Neuroendocrine Mechanisms to Clinical Application.
pmc 2026
Connected data hub
Records with source provenance.
Reviewed records carry an admin-reviewed badge. Automated records link back to the provider for independent checking.
Clinical Trial
54 recordsclinicaltrialsAdmin reviewed
Optimizing Albuminuria Treatment in CKD With Finerenone and Semaglutide
The FINESSE-CKD trial investigates a personalized approach to the treatment of chronic kidney disease (CKD) by comparing the effects of finerenone and semaglutide on albuminuria. Approximately 36 participants will receive both treatments in a randomized crossover design, with...
clinicaltrialsAdmin reviewed
A Study of BGM0504 in Early T2DM With Obesity
This trial is conducted in China. The aim is to compare BGM0504 Injection 15 mg with semaglutide 1.0 mg in Chinese T2DM patients with obesity and inadequate control despite diet and exercise. Over 52 weeks of once weekly...
clinicaltrialsAdmin reviewed
Semaglutide and Structured Lifestyle Support to Improve Heart and Blood Vessel Health in Postmenopausal Obese Breast Cancer Survivors Taking Aromatase Inhibitors
This phase IV trial studies whether adding semaglutide to structured lifestyle support improves heart and blood vessel health in postmenopausal obese breast cancer survivors (BCS) who are taking an aromatase inhibitor. In postmenopausal BCS who are taking an...
clinicaltrialsAdmin reviewed
Effects of GLP-1 RAs on Human Lactation Outcomes
There is increasing interest in using GLP-1 Receptor Agonist (GLP-1 RA) medications after pregnancy. This study is designed to determine if these medications affect breastmilk production or the nutritional makeup of breastmilk. The main questions the study will...
clinicaltrialsAdmin reviewed
Evaluating the Efficacy and Safety of LUM-201 Plus Semaglutide Versus Semaglutide Plus Placebo in Older Obese Adults
This is a phase 2 randomized, double-blind, placebo-controlled, multi-center study evaluating the efficacy and safety of LUM-201 plus Semaglutide versus Semaglutide plus placebo in obese adults with body mass index between 30 and 45 kg/m\^2, between the ages...
clinicaltrialsAdmin reviewed
Non-Invasive Hepatic and Metabolic Index Changes After Incretin Therapy in Overweight/Obesity
This single-center, retrospective observational cohort study evaluated early changes in non-invasive hepatic and metabolic indices (FIB-4, APRI, HSI, and the triglyceride-glucose \[TyG\] index) in adults with overweight or obesity who received once-weekly subcutaneous semaglutide or tirzepatide for metabolic...
clinicaltrialsAdmin reviewed
BALANCE-DM2 Study of Bofanglutide in Adults With Type 2 Diabetes
The goal of this clinical trial is to evaluate the efficacy and safety of Bofanglutide (GZR18) compared with Semaglutide in Latin American adults with type 2 diabetes mellitus who have inadequate glycemic control while receiving stable metformin monotherapy....
clinicaltrialsAdmin reviewed
Translational Health Research Into Vascular and Neurocognitive Effects of Weight Loss
The goal of this clinical trial is to learn about the nature of brain abnormalities associated with excess body fat in healthy adults aged 35-55. The main questions it aims to answer are: * Will excessive fat be...
clinicaltrialsAdmin reviewed
Effects of Semaglutide on Clinical Outcomes and Metabolic Inflammation in Psoriasis
This study will evaluate the effects of oral semaglutide in combination with topical corticosteroid/calcipotriol on clinical outcomes and metabolic inflammation in patients with plaque psoriasis and overweight/obesity and/or type 2 diabetes mellitus. A total of 62 participants will...
clinicaltrialsAdmin reviewed
Bariatric Surgery Combined With GLP-1 Receptor Agonists Study
Obese patients exhibit considerable heterogeneity and complex comorbidities, making long-term effective management challenging with single therapies. While bariatric surgery remains the most effective weight-loss intervention, postoperative weight regain and metabolic deterioration require attention. GLP-1 RAs offer distinct advantages...
clinicaltrialsAdmin reviewed
A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term
This study will look at how well CagriSema helps people living with obesity to lose weight and maintain the weight loss long-term. The study has 2 parts: The first part is called 'the main study' and the second...
clinicaltrialsAdmin reviewed
Protein Supplementation Intervention on Body Weight
This study is a randomized clinical trail with a parallel design, involving 120 overweight/obese (body-mass index, BMI ≥ 24 kg/m²) participants and 20 normal-weight participants. Overweight/obese participants will be randomly allocated to one of three groups: 1) calorie...
clinicaltrialsAdmin reviewed
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
The purpose of this study is to measure the change in hemoglobin A1c (HbA1c) with LY3457263 compared with placebo in participants with type 2 diabetes who are not at HbA1c goal when treated with a stable dose of...
clinicaltrialsAdmin reviewed
Sleeve Gastrectomy vs. Lifestyle & Medications: Impact on BMI Trajectory and Target Attainment in a Matched Cohort Study
Obesity is a widespread and preventable condition affecting over a billion people globally, with rates expected to rise significantly by 2030. It increases the risk of chronic illnesses such as diabetes, cardiovascular disease, certain cancers, mental health issues,...
clinicaltrialsAdmin reviewed
Effects of Long-Acting GLP-1 (Glucagon-like Peptide-1) or Dual Incretin (GLP-1 and GIP [Glucose-dependent Insulinotropic Peptide]) Modulation on Gastric Motor Functions
The purpose of this study is to compare effects of weekly SQ semaglutide 2.4mg SQ, SQ tirzepatide 10mg, and placebo administered for 24 weeks on GES measured repeatedly at baseline, 16 weeks, 24 weeks, 28 weeks, 4 weeks...
clinicaltrialsAdmin reviewed
Comparison of the Safety, Efficacy and Pharmacokinetics of DehydraTECH -CBD and DehydraTECH-GLP1 Agonists Alone or in Combination, in Overweight or Obese, Pre- and Type 2 Diabetic Participants
This is a Phase 1b, randomized, open-label, active-controlled, parallel, multiple-dose study comparing the safety, pharmacokinetics and efficacy of DehydraTECH Cannabidiol and Glucagon-like Peptide 1 (GLP-1) agonists alone and in combination, in overweight or obese, pre- and type 2...
clinicaltrialsAdmin reviewed
Obesity Management for Kidney TRANSPLANTation: OK-TRANSPLANT 2
OK-TRANSPLANT 2 is a vanguard study for a large randomized, pragmatic, open-label trial. We will randomize participants with obesity, high-risk CKD/dialysis who are hoping for lose weight for the purpose of kidney transplant. Subjects will either be enrolled...
clinicaltrialsAdmin reviewed
A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight
This study will look at how well CagriSema helps people with excess body weight lose weight. CagriSema is a new medicine developed by Novo Nordisk that combines cagrilintide and semaglutide. CagriSema cannot yet be prescribed by doctors. In...
clinicaltrialsAdmin reviewed
Study That Tests AD109 in Patients Taking GLP-1 Drugs
Phase 2 Safety, Efficacy and, Tolerability of Fixed Dose Combination of Aroxybutynin/Atomoxetine (AD109) in Obstructive Sleep Apnea Patients Taking Tirzepatide, Semaglutide or Liraglutide
clinicaltrialsAdmin reviewed
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise
This study will look at how much CagriSema helps participants with type 2 diabetes lower their blood sugar and body weight. CagriSema is a new investigational medicine. Doctors may not yet prescribe CagriSema. CagriSema will be compared to...
clinicaltrialsAdmin reviewed
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without Metformin
This study will look at how much CagriSema helps people with type 2 diabetes lower their blood sugar and body weight. CagriSema is a new investigational medicine. Doctors may not yet prescribe CagriSema. CagriSema will be compared to...
clinicaltrialsAdmin reviewed
A Research Study to See How Well Semaglutide Helps People Who Have a Body Weight Above the Healthy Weight Range
This study will look at how the investigational dose of semaglutide works in helping people with excess body weight, to lose weight. This study will compare the weight loss in people taking semaglutide to people taking "dummy" medicine...
clinicaltrialsAdmin reviewed
Feasibility of Aggressive Albuminuria Reduction in Biopsy-Proven Diabetic Nephropathy - a Pilot Study
The purpose of this trial is to investigate the feasibility and safety of implementing a protocol-based treatment aggressively targeting albuminuria in subjects with biopsy-proven diabetic nephropathy and severely elevated albuminuria. If this approach is feasible, the results of...
clinicaltrialsAdmin reviewed
O-SEMA-Fast: A Research Study to Understand How Oral Semaglutide Works in People With Type 2 Diabetes Who Plan to Fast During Ramadan in the United Arab Emirates, Saudi Arabia, and Kuwait
The purpose of the study is to look at the change in blood sugar levels in people with type 2 diabetes who are using oral semaglutide and planning to fast during Ramadan. Participants will take oral semaglutide as...
clinicaltrialsAdmin reviewed
A Research Study to See How Semaglutide Helps People With Excess Weight, Lose Weight (STEP UP)
This study will look at how much weight participants will lose from the start to the end of the study. The weight loss in participants taking the investigational high dose of semaglutide will be compared to the weight...
clinicaltrialsAdmin reviewed
COMMETS- Combination MCI Metabolic Syndrome
The investigators propose a proof of concept RCT (randomized clinical trial), testing the efficacy of intranasal insulin (INI) with semaglutide, a combination therapy with strong biological plausibility to benefit impaired cognition through vascular mechanisms, in older adults with...
clinicaltrialsAdmin reviewed
Sex Steroids Balance for Metabolic and Reproductive Health in Klinefelter Syndrome
The study seeks primarily to determine whether modulation of systemic and testicular sex steroids balance by aromatase inhibitors will positively affect the metabolic health and spermatogenesis of men with Klinefelter syndrome (KFS) as compared to the current state...
clinicaltrialsAdmin reviewed
Does the Hematopoietic Stem Cell Govern Residual Inflammatory Cardiovascular Risk in Type 2 Diabetes
To study the effect of type 2 diabetes (T2D) on vascular wall inflammation and hematopoietic stem cell composition in vivo, and whether these changes can be reversed with glucagon like peptide 1 receptor (GLP1R)-agonism.
clinicaltrialsAdmin reviewed
Young Adults With Early-onset Obesity Treated With Semaglutide
Introduction: The increasing prevalence of obesity is particularly pronounced among adolescents. Currently available treatment options consist of structured lifestyle interventions. However, 25 % of adolescents do not respond to lifestyle treatment, why new effective treatment strategies are needed....
clinicaltrialsAdmin reviewed
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Finland, as Part of Local Clinical Practice
The purpose of the study is to collect information on how Rybelsus® works in people with type 2 diabetes and to see if Rybelsus® can lower their blood sugar levels. Participants will get Rybelsus® as prescribed to them...
clinicaltrialsAdmin reviewed
Brown Adipose Tissue Activity in Response to Semaglutide Administered to Obese Subjects.
Glucagon like peptide (GLP-1) agonists, such as liraglutide, exenatide, and semaglutide, have been increasingly used as a medication to address the current twin epidemics of diabetes and obesity. Their activities include increasing insulin production by pancreatic beta cells,...
clinicaltrialsAdmin reviewed
A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Insulin Icodec
This study will compare the new medicine IcoSema, which is a combination of insulin icodec and semaglutide, taken once a week, to insulin icodec taken once a week in people with type 2 diabetes. The study will look...
clinicaltrialsAdmin reviewed
Interest of GLP1 Analogues in Overweight Type 2 Diabetic Patients With Chronic Inflammatory Bowel Disease
The risk of type 2 diabetes appears to be higher in patients with chronic inflammatory diseases, including chronic inflammatory bowel disease (IBD). IBD is a group of inflammatory diseases that includes mainly Crohn's disease and ulcerative colitis. Although...
clinicaltrialsAdmin reviewed
BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes
An observational study of electronic patient data to compare diabetes medications and to determine which ones offer the best balance of risks and benefits.
clinicaltrialsAdmin reviewed
Pharmacogenetics of Response to GLP1R Agonists
Overweight/obese otherwise healthy volunteers will be recruited from the Old Order Amish population in Lancaster County, PA. Lancaster County, PA. Pharmacodynamic responses to GLP1R agonist will be assessed by conducting frequently sampled intravenous glucose tolerance tests (FSIGT) both...
clinicaltrialsAdmin reviewed
Comparison of Oral Semaglutide w/ Placebo- Treatment for Latino Adults w/T2 Diabetes Receiving Enhanced Lifestyle Care
Researchers at Sansum Diabetes Research Institute want to learn more about how taking a new approved drug called oral Semaglutide, while eating fresh vegetables, impacts health in Hispanic/Latino adults with type 2 diabetes. This study drug is approved...
clinicaltrialsAdmin reviewed
Semaglutide for the Reduction of Arrhythmia Burden in Overweight AF Patients
The purpose of this pilot study is to assess the feasibility of a double-blind, randomized placebo-controlled trial of semaglutide 2.4 mg subcutaneously once weekly on top of standard care compared to standard care alone.
clinicaltrialsAdmin reviewed
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)
This study is done to find out whether the medicine, semaglutide, has a positive effect on early Alzheimer's disease. Participants will either get semaglutide or placebo (a "dummy" medicine which does not contain any study medicine) - which...
clinicaltrialsAdmin reviewed
Effect of Subcutaneous Semaglutide on Kidney Transplant Candidacy
This randomized study evaluates the effect of subcutaneous semaglutide /in combination with lifestyle counseling in patients with type 2 diabetes mellitus (T2DM), overweight/obesity, and stage 4-5 chronic kidney disease (CKD) or dialysis-dependent end-stage kidney disease (ESKD) on patients'...
clinicaltrialsAdmin reviewed
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Sweden, as Part of Local Clinical Practice
The purpose of the study is to collect information on how Rybelsus® works in people with type 2 diabetes and to see if Rybelsus® can lower their blood sugar levels. Participants will get Rybelsus® as prescribed to them...
clinicaltrialsAdmin reviewed
A Research Study to Compare a Medicine Called Semaglutide Against Placebo in People With Peripheral Arterial Disease and Type 2 Diabetes
This study is done to see if semaglutide has an effect on walking ability compared with placebo (dummy medicine) in people with peripheral arterial disease (PAD) and type 2 diabetes. Participants will either get semaglutide or placebo ("dummy")...
clinicaltrialsAdmin reviewed
Transition From Basal/Bolus to Once-weekly Subcutaneous Semaglutide and Basal Insulin in Patients With T2D
This study is designed to determine whether therapy with once-weekly sc semaglutide in combination with once-daily insulin degludec will be capable of maintaining (or improving) glycemic control, when substituted for multiple daily injections of insulin (MDI), in patients...
clinicaltrialsAdmin reviewed
16-week Flexible vs. 8-week Semaglutide Titration
Semaglutide is a Glucagon Like Peptide 1 (GLP-1) receptor agonist recently approved in Israel to improve glycemic control in patients with type 2 diabetes mellitus. Semaglutide is currently administered as a weekly subcutaneous injection.Treatment with semaglutide is associated...
clinicaltrialsAdmin reviewed
SUSTAIN SWITCH: A Research Study to Compare Two Dose Schedules of Semaglutide Taken Once Weekly in People With Type 2 Diabetes
This study compares the effect and safety of 2 dose schedules for semaglutide (study medicine) in people with type 2 diabetes previously treated with a diabetes medicine similar to semaglutide. The study will also evaluate the use of...
clinicaltrialsAdmin reviewed
A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (C) Semaglutide Tablets
In this study two different tablets for oral use of a known investigational medicinal product, called semaglutide, will be tested. Besides semaglutide, the current version of the tablet contains 300 mg SNAC and 3 helping agents, while the...
clinicaltrialsAdmin reviewed
A Research Study to Compare Two Forms of Semaglutide in Two Different Pen-injectors in People With Overweight or Obesity
The study will look at how two different forms of semaglutide reach and stay in the blood after injection. None of the two forms of semaglutide have been approved by the authorities to treat obesity. Participants will get...
clinicaltrialsAdmin reviewed
A Research Study to Compare Semaglutide to Insulin Aspart, When Taken Together With Metformin and Insulin Glargine, in People With Type 2 Diabetes
This study will compare the effect of semaglutide once weekly to insulin aspart 3 times daily as add on to metformin and insulin glargine in people with type 2 diabetes. Participants will either get insulin glargine and semaglutide...
clinicaltrialsAdmin reviewed
Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic Trial
The main purpose of this study is to compare the effects of semaglutide (Ozempic®) with the effects of other treatments for type 2 diabetes in a normal practice setting. The participant will be assigned by chance (like flipping...
clinicaltrialsAdmin reviewed
A Trial Investigating the Influence of Oral Semaglutide on the Pharmacokinetics of Levothyroxine and the Influence of Co-administered Tablets on the Pharmacokinetics of Semaglutide Administered Orally in Healthy Subjects.
This trial is conducted in Europe. The aim of this trial is to investigate the influence of oral semaglutide on the pharmacokinetics (the exposure of the trial drug in the body) of levothyroxine and the influence of co-administered...
clinicaltrialsAdmin reviewed
Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes
This trial is conducted globally. The aim of the trial is to investigate efficacy and long-term safety of oral semaglutide versus sitagliptin in subjects with type 2 diabetes.
clinicaltrialsAdmin reviewed
Effect of Food on the Pharmacokinetics of Oral Semaglutide in Healthy Subjects
This trial is conducted in Europe. The aim of the trial is to investigate the effect of food on the pharmacokinetics (the exposure of the trial drug in the body) of oral semaglutide, in a SNAC (sodium N-\[8-(2-hydroxybenzoyl)...
clinicaltrialsAdmin reviewed
Trial Investigating the Effect of Semaglutide on Energy Intake, Appetite Sensations, Postprandial Glucose and Triglyceride Metabolism and Gastric Emptying in Obese Subjects Compared With Placebo
This trial is conducted in Europe. The aim of the trial is to investigate the effect of semaglutide on energy intake, appetite sensations, postprandial glucose and triglyceride metabolism and gastric emptying in obese subjects compared with placebo.
clinicaltrialsAdmin reviewed
Pharmacoscintigraphic Investigation of NN9924 in Healthy Male Subjects
This trial is conducted in Europe. The aim of this trial is to investigate whether the volume of water administered with NN9924 affects the anatomical location (stomach or proximal small bowel) of tablet erosion.
clinicaltrialsAutomated import
Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists
Minorities have higher rates of diabetes, poorer glucose control, and higher complications and mortality rates than white people. Several recently approved diabetes medicines improve cardiovascular and renal outcomes through two different mechanisms. This study will explore key determinants...
Regulatory Label
5 recordsopenfdaAdmin reviewed
Ozempic — Dosage and Administration
2 DOSAGE AND ADMINISTRATION • Administer once weekly at any time of day, with or without meals. ( 2.1 ) • Start at 0.25 mg once weekly. After 4 weeks, increase the dosage to 0.5 mg once weekly....
openfdaAdmin reviewed
OZEMPIC — Dosage and Administration
2 DOSAGE AND ADMINISTRATION • RYBELSUS and OZEMPIC tablets are not substitutable on a mg-to-mg basis. • Take RYBELSUS or OZEMPIC tablets orally once daily on an empty stomach in the morning with water (up to 4 ounces...
openfdaAdmin reviewed
WEGOVY — Dosage and Administration
2 DOSAGE AND ADMINISTRATION • Administer WEGOVY once weekly as an adjunct to diet and increased physical activity, on the same day each week, at any time of day, with or without meals (2.1). • Inject subcutaneously in...
openfdaAdmin reviewed
Ozempic — Dosage and Administration
2 DOSAGE AND ADMINISTRATION • Administer once weekly at any time of day, with or without meals ( 2.1 ). • Start at 0.25 mg once weekly. After 4 weeks, increase the dosage to 0.5 mg once weekly...
openfdaAdmin reviewed
OZEMPIC — Dosage and Administration
2 DOSAGE AND ADMINISTRATION • Administer once weekly at any time of day, with or without meals ( 2.1 ). • Start at 0.25 mg once weekly. After 4 weeks, increase the dosage to 0.5 mg once weekly...
Open Access Article
10 recordspmcAutomated import
Efficacy of Semaglutide in Modulating Cardiac Remodeling in Mice: A Review of Mechanisms and Outcomes.
Fairy R, Ali L, Azam H, Khurram A, Shahzaib M, Tariq H, Rashmeen S, Hassan H · Research in heart yield and translational medicine
pmcAutomated import
GLP-1 and Dual GIP/GLP-1 Receptor Agonists in Pediatric Obesity: From Neuroendocrine Mechanisms to Clinical Application.
Myśliwczyk D, Myśliwiec M, Minarowska A, Wasilewska E · International Journal of Molecular Sciences
pmcAutomated import
GLP-1 Receptor Agonists in Epilepsy: Separating Evidence for Antiseizure Activity, Neuroprotection, and Disease Modification.
Gorgul YA, Zaitsev AV · International Journal of Molecular Sciences
pmcAutomated import
Exploratory Biomarker-Defined Phenotypic Heterogeneity Beyond a Single Physiological Reserve Construct.
AlTaweel MO, Ahmed Jalbani A, Memon F, Aly Mahmoud A, Memon P, Elnasharty I, Elshehawey A, Al Qarni A · Journal of Personalized Medicine
pmcAutomated import
Salcaprozate Sodium as a Permeation Enhancer—Mechanism, Applications and Unresolved Questions.
Dinkov B, Koleva N, Stavreva G · Pharmaceutics
pmcAutomated import
Semaglutide Attenuates Inflammatory Macrophage Polarization and Promotes Changes Associated with Mitochondrial Biogenesis Through cAMP-Dependent Signaling.
Pavshintsev VV, Erbaeva AZ, Vatlin AA, Mitkin NA · Biomedicines
pmcAutomated import
GLP-1 Receptor Agonists as Molecular Relievers of Lipotoxic Stress: From Pancreatic Beta-Cell Cholesterol Efflux to Systemic and Tissue-Specific Metabolic Protection.
Jiang W, Fukunaga K, Kobayashi T, Saheki T, Yoshimura T, Zhang H, Ly R, Imachi H, Murao K · International Journal of Molecular Sciences
pmcAutomated import
Pathogenesis-Informed Phenotype-Guided Therapy for MASH: A Three-Axis Translational Framework Within the MASLD Spectrum.
Zhao Z, Hu X · Biomedicines
pmcAutomated import
Beyond weight loss: Disentangling the direct effects of semaglutide vs equivalent calorie restriction on reproductive systems of male and female rats.
Sotzen MR, Byun S, Ibadin NO, Knappenberger MA, Bento MT, Asker M, Koshkin S, Diaz FJ, Skibicka KP · Molecular metabolism
pmcAutomated import
Pharmacological management of obesity: Current landscape and emerging therapies.
Atal S, Agrawal C, Gupta R, Sadasivam B · Indian journal of pharmacology
Publication
16 recordspubmedAutomated import
A new era in the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD): clinical breakthroughs and challenges.
You Z, Yang L, Long Y, You D, Zhao Q
pubmedAutomated import
Impact of Semaglutide, Liraglutide and Tirzepatide on Cardiometabolic Outcomes: A Comparative Narrative Review.
Bawadi H, Abuhijleh H, Nofal M, Zakaria ZZ, Al-Asmakh M
pubmedAutomated import
Assessing the Growing Impact of Oral GLP-1 Agonists on National Obesity Policies of the United Kingdom.
Mathew A, Anwar H
pubmedAutomated import
Investigating the Association Between Semaglutide Use and Mood Disorders in Polyendocrine Metabolic Ovarian Syndrome: A Retrospective Cohort Study.
Raj FP, Boo H, Kenney A, Espiridion E
pubmedAutomated import
Suitability of the ICH S1B(R1) Weight-of-Evidence Framework to Evaluate Glucagon-Like Protein-1 Receptor Agonist (GLP-1RA) Carcinogenicity Risk.
Roach KA, Khazaee M, Mohar I, Boon D, Cronin B, Gauthier AG
pubmedAutomated import
Oral semaglutide vs DPP-4 inhibitors in reducing risk of cognitive impairment in elderly patients with HFpEF and obesity.
Ayyaz F, Khan H, Zia I
pubmedAutomated import
Glucagon-like Peptide-1 Receptor Agonists and Upper Gastrointestinal Endoscopy: A Narrative Review of Residual Gastric Contents Aspiration Risk and Periprocedural Management.
Bandaranaike R, Rutland T, Rutland B
pubmedAutomated import
Salcaprozate Sodium as a Permeation Enhancer-Mechanism, Applications and Unresolved Questions.
Dinkov B, Koleva N, Stavreva G
pubmedAutomated import
Clinical Profile of Documented Diabetic Peripheral Neuropathy by GLP-1-Based Medication Status: A Cross-Sectional Study.
Ferician AC, Ghitea TC, Popoviciu MS
pubmedAutomated import
Cardiovascular-Kidney-Metabolic Syndrome and Its Hepatic Dimension: A Narrative Review.
Enache V, Popescu DC, Marcu B, Diaconu M, Nechita AC
pubmedAutomated import
GLP-1 Receptor Agonists and Tirzepatide in Men Seeking Fertility: A Structured Narrative Review and Proposed Clinical Framework.
Kaltsas A, Gkioxaris V, Giannakas T, Zachariou A, Dimitriadis F, Sofikitis N, Chrisofos M
pubmedAutomated import
GLP-1 Receptor Agonists as Molecular Relievers of Lipotoxic Stress: From Pancreatic Beta-Cell Cholesterol Efflux to Systemic and Tissue-Specific Metabolic Protection.
Jiang W, Fukunaga K, Kobayashi T, Saheki T, Yoshimura T, Zhang H, Ly R, Imachi H, Murao K
pubmedAutomated import
Adjunctive GLP-1 receptor agonists for cardiometabolic risk in antipsychotic-treated patients: A GRADE-assessed meta-analysis of randomized trials.
Moubarak ES, Elgendy MS, Elkoumi O, Ibrahim AA, Manasrah A, Ahmad J, Hassan MA, Rageh OE, Mohamed AA, Elzahaby A, Abuelazm M
pubmedAutomated import
Cagrilintide and retatrutide combination therapy enhances weight loss and metabolic outcomes in obese male rats.
Petersen J, Merrild C, Holm SK, Kurgan N, Hassan S, Mathiesen CV, Börchers S, Svendsen C, D'Anna S, Andersen NR, Klein AB, Fritzen AM, Deshmukh AS, Pers TH, Clemmensen C
pubmedAutomated import
Beyond Weight Loss: Thromboinflammation as a Candidate Mechanism for the Cardiovascular Benefit of GLP-1 Receptor Agonists.
Melnikov I, Borodko D, Alekseev V
pubmedAutomated import
Combination GLP-1RA and Low-Dose IL-2 Modulates Peripheral Immune Activation and Attenuates CNS Inflammatory Transcript Signatures In Vivo.
Thome AD, Wang J, Faridar A, Zhao W, Saetzler V, Beers DR, Appel SH
Scholarly Work
8 recordscrossrefAutomated import
Review for "Semaglutide 25 mg Oral versus Semaglutide 2.4 mg Injectable: An Indirect Treatment Comparison of Weight Loss Outcomes"
· Wiley
crossrefAutomated import
Review for "Semaglutide 25 mg Oral versus Semaglutide 2.4 mg Injectable: An Indirect Treatment Comparison of Weight Loss Outcomes"
· Wiley
crossrefAutomated import
Review for "Semaglutide 25 mg Oral versus Semaglutide 2.4 mg Injectable: An Indirect Treatment Comparison of Weight Loss Outcomes"
· Wiley
crossrefAutomated import
Orale semaglutide versus subcutane semaglutide
M van den Berg · Geneesmiddelenbulletin Foundation
crossrefAutomated import
Semaglutide
· Springer Science and Business Media LLC
crossrefAutomated import
Semaglutide
· Springer Science and Business Media LLC
crossrefAutomated import
semaglutide
· Royal Pharmaceutical Society
crossrefAutomated import
semaglutide
· Royal Pharmaceutical Society
Article
8 recordsopenalexAutomated import
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes
Vlado Perkovic, Katherine R. Tuttle, Peter R Rossing, Kenneth W. Mahaffey, Johannes F.E. Mann, George L. Bakris et al. · New England Journal of Medicine · 1828 citations
openalexAutomated import
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Abraham Michael Lincoff, Kirstine Brown‐Frandsen, Helen Martina Colhoun, John Eric Deanfield, Scott S. Emerson, Sille Esbjerg et al. · New England Journal of Medicine · 3061 citations
openalexAutomated import
Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity
Mikhail Kosiborod, Steen Zabell Abildstrom, Barry A. Borlaug, Javed Butler, Søren Rasmussen, Melanie J. Davies et al. · New England Journal of Medicine · 1621 citations
openalexAutomated import
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Juan P. Frías, Melanie J. Davies, Julio Rosenstock, Federico C. Pérez Manghi, Laura Fernández Landó, Brandon K. Bergman et al. · New England Journal of Medicine · 2036 citations
openalexAutomated import
Once-Weekly Semaglutide in Adults with Overweight or Obesity
John P.H. Wilding, Rachel Louise Batterham, Salvatore Calanna, Melanie J. Davies, Luc F. Van Gaal, Ildiko Lingvay et al. · New England Journal of Medicine · 5058 citations
openalexAutomated import
A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis
Philip Noel Newsome, Kristine Buchholtz, Kenneth J. Cusi, Martin Linder, Takeshi Okanoue, Vlad Ratziu et al. · New England Journal of Medicine · 2009 citations
openalexAutomated import
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Mansoor Husain, Andreas L. Birkenfeld, Morten Donsmark, Kathleen Marie Dungan, Freddy Goldberg Eliaschewitz, Denise Reis Franco et al. · New England Journal of Medicine · 2009 citations
openalexAutomated import
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Steven P. Marso, Stephen Charles Bain, Agostino Consoli, Freddy Goldberg Eliaschewitz, Esteban Jódar, Lawrence A. Leiter et al. · New England Journal of Medicine · 6912 citations
Live discovery
Latest research signals
Live results from PubMed, ClinicalTrials.gov and UniProt. These may not yet have been reviewed or stored in the Data Hub.
Recent PubMed records
Cutaneous Adverse Events With Semaglutide: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.PMID 42966951 · 2026 SepLithium Toxicity Following Initiation of Semaglutide in a Patient With Bipolar Disorder: A Case Report.PMID 42964850 · 2026 SepPigmented purpura dermatosis associated with compounded semaglutide: A case report and literature review of medication-associated pigmented purpuric dermatosis.PMID 42964517 · 2026 NovBeyond glycemic control: cardiovascular and kidney benefits of GLP-1 receptor agonists and the dual GIP/GLP-1 receptor agonist tirzepatide: a narrative review.PMID 42964480 · 2026Activities of daily living and health status benefits of semaglutide in very old patients with heart failure, type 2 diabetes, and obesity: Real-world practice study.PMID 42963299 · 2026 Oct 30Registered clinical studies
CRAVE Study: Comparing Craving Responses and Diet Quality of GLP1 Receptor Agonist UsersNCT06467604 · ACTIVE_NOT_RECRUITINGDoes Semaglutide Improve Depressive Symptoms in Patients With Major Depressive Disorder and Overweight or ObesityNCT07136714 · RECRUITINGA Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Semaglutide (COMBINE 2)NCT05259033 · COMPLETEDReviewed UniProt records
Responsible use of information
Fitzbio provides educational and research reference material. It does not diagnose, prescribe or replace advice from a qualified healthcare professional.